Constitutive and oxidative-stress-induced expression of VEGF in the RPE are differently regulated by different Mitogen-activated protein kinases

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 247, Issue 11, 2009, Pages 1487-1492

  Klettner, Alexa ^a   Roider, Johann ^a  

^a UKS H   (Germany)

Author keywords

Erk; JNK; MAPK; Oxidative stress; P38; VEGF

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENZYME INHIBITION; NONHUMAN; ORGAN CULTURE; OXIDATIVE STRESS; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RETINA MACULA AGE RELATED DEGENERATION; SWINE; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTHRACENES; BLOTTING, WESTERN; BUTADIENES; CELL CULTURE TECHNIQUES; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; NITRILES; ORGAN CULTURE TECHNIQUES; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RETINAL PIGMENT EPITHELIUM; SWINE; TERT-BUTYLHYDROPEROXIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70349884317     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-009-1139-x     Document Type: Article

References (36)

1. Lin RC, Rosenfeld PJ (2007) Antiangiogenic therapy in neovascular age-related macular degeneration. Int Ophthalmol Clin 47:117-137, doi: 10.1097/IIO.0b013e31802bd873
2. Steinbrook R (2006) The price of sight. N Engl J Med 355:1409-1412, doi: 10.1056/NEJMp068185
3. El-Remessy AB, Bartoli M, Platt DH, Fulton D, Caldwell RB (2004) Oxidative stress inactivates VEGF survival signaling in rential endothelial cells via PI 3-kinase tyrosine nitration. J Cell Sci 118:243-252, doi: 10.1242/jcs.01612
4. Zachary I (2004) Neuroprotective role of VEGF: Signalling mechanisms, biological function, and therapeutic potential. Neurosignals 14:207-221, doi: 10.1159/000088637
5. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal Bevacizumab (Avastin) for neovascular AMD. Ophthalmol 113:363-372
6. Spitzer MS, Yoeruek E, Sierra A, Wallenfels B, Schraermeyer U, Spitzer B, Bartz-Schmidt KU, Szurman P (2007) Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol 245:1835-1842
7. Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU, Schraermeyer U (2007) Ultrastructural findings in the primate eye after intravitreal injections of bevacizumab. Am J Ophthalmol 143:995-1002, doi: 10.1016/j.ajo.2007.03.007
8. Josko J, Mazurek M (2004) Transcription factors having impact on VEGF gene expression in angiongenesis. Med Sci Monit 10:RA89-RA98
9. Pages G, Berra E, Milanini J, Levy AP, Pouyssegur J (2000) Stress activated Protein Kinases (JNK and p38/HOG) are essential for Vascular Endothelial Growth Factor (VEGF) mRNA stability. J Biol Chem 275:26484-26491, doi: 10.1074/jbc.M002104200
10. Poulaki V, Joussen AM, Mitsiades N, Mitsiades CS, Iliaki EF, Adamis AP (2004) Insulin-like Growth Factor -1 (IGF-1) plays a pathogenetic role in diabetic retinopathy. Am J Pathol 165:457-469
11. Poulaki V, Qin W, Joussen AM, Hurlbut P, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis A (2002) Acute insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia - inducible factor 1 alpha and VEGF. J Clin Invest 109:805-815
12. Nagineni CN, Nagineni S, Samuel W, Pardhasaradhi K, Wiggert B, Detrick B, Hooks JJ (2003) TGFÓ induces expression of VEGF in human RPE cells: Involvement of MAPK. J Cell Physiol 197:453-462, doi: 10.1002/ jcp.10378
13. Treins C, Giorgetti-Peraldi S, Murdaca J, Van Obberghen E (2001) Regulation of VEGF expression by advanced glycation End products. J Biol Chem 276:43836-43841, doi: 10.1074/jbc.M106534200
14. Klettner A, Roider J (2008) Comparison of Bevacizumab, Ranibizumab and Pegaptanib in vitro: Efficiency and possible additional pathways. Invest Ophthalmol Vis Sci 49:4523-4527, doi: 10.1167/iovs.08-2055
15. Klettner A, Herdegen T (2003) The immunophilin-ligands FK506 and V-10, 367 mediate neuroprotection by the heat shock response. Br J Pharmacol 138:1004-1012, doi: 10.1038/sj.bjp. 0705132
16. McColl B, Stacker S, Achen M (2004) Molecular regulation of the VEGF family - inducers of angiogenesis and lymphangiogenesis. APMIS 112:463-480, doi: 10.1111/j.1600-0463.2004.apm11207-0807.x
17. Fletcher EC, Chong NV (2008) Looking beyong Lucentis on the management of AMD. Eye 22:742-750, doi: 10.1038/sj.eye.6703008
18. Caldwell RB, Bartoli M, Behzadian A, El-Remessy AB, Al-Shabrawey M, Platt DH, Liou G, Caldwell RW (2005) VEGF and diabetic retinopathy: Role of oxidative stress. Curr Drug Targets 6:511-524, doi: 10.2174/ 1389450054021981
19. Bian ZM, Elner SG, Elner VM (2007) Thrombin-induced VEGF expression in human RPE. Invest Ophthalmol Vis Sci 48:2738-2746, doi: 10.1167/ iovs.06-1023
20. Bian ZM, Elner SG, Elner VM (2007) Regulation of VEGF mRNA expression and protein secretion by TGF-beta2 in human retinal pigment epithelial cells. Exp Eye Res 84:812-822, doi: 10.1016/j.exer.2006.12.016
21. Murata M, Yudoh K, Nakamura H, Kato T, Inoue K, Chiba J, Nishioka K, Masuko-Hongo K (2006) Distinct signaling pathways are involved in hypoxia- and IL-1-induced VEGF expression in human articular chondrocytes. J Orthop Res 24:1544-1554, doi: 10.1002/jor.20168
22. Fan B, Wang YX, Yao T, Zhu YC (2005) p38 Mitogen-activated protein kinase mediates hypoxia-induced vascular endothelial growth factor release in human endothelial cells. Sheng Li Xue Bao 57:13-20
23. Kook SH, Son YO, Jang YS, Lee KY, Lee SA, Kim BS, Lee HJ, Lee JC (2008) Inhibition of JNK sensitized tumor cells to flavonoid-induced apoptosis through down-regulation of JunD. Toxicol Appl Pharmacol 227:468-476, doi: 10.1016/j.taap. 2007.11.004
24. Hilfiker-Kleiner D, Hilfiker A, Kaminstki K, Schaefer A, Park JK, Michel K, Quint A, Yaniv M, Weitzman JB, Drexler H (2005) Lack of JunD promotes pressure overload - induced apoptosis, hypertrophic growth and angiogenesis in the heart. Circulation 112:1470-1477, doi: 10.1161/ CIRCULATIONAHA.104.518472
25. Gerald D, Berra E, Frapart YM, Chan DA, Giacca AJ, Mansury D, Pouyssegur J, Yaniv M, Mechta-Grigoriou F (2004) JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 118:781-794, doi: 10.1016/ j.cell.2004.08.025
26. Milanini J, Vinals F, Pouyssegur J, Pages G (1998) p42/p44 MAP Kinase module plays a key role in the transcriptional regualtion of the cascular endothelial growth factor (VEGF) gene in fibroblasts. J Biol Chem 273:18165-18172, doi: 10.1074/jbc.273.29.18165
27. Berra E, Pages G, Pouyssegur J (2000) MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Res 19:139-145, doi: 10.1023/A:1026506011458
28. Sodhi A, Montaner S, Miyazaki H, Gutkind JS (2001) MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1α in ras V12 upregulation of VEGF. Biochem Biophys Res Commun 287:292-300, doi: 10.1006/bbrc.2001.5532
29. Sutton KM, Hayat S, Chau NM, Cook S, Pouyssegur J, Ahmed A, Perusinghe N, Le Floch R, Yang J, Ashcroft M (2007) Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF-1. Oncogene 26:3920-3929, doi: 10.1038/sj.onc.1210168
30. Forsythe J, Jiang B, Iyer N, Agani F, Leung S, Koos R, Semenza G (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604-4613
31. Bonello S, Záhringer C, BelAiba R, Djordjevic T, Hess J, Michiels C, Kietzmann T, Górlach A (2007) Reactive oxygen species activate the HIF-1α promoter via a functional NFkB site. Arterioscler Thromb Vasc Biol 27:755-761, doi: 10.1161/01.ATV.0000258979.92828.bc
32. McMahon S, Charbonneau M, Grandmont S, Richard D, Dubois C (2006) Transforming growth factor beta 1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression. J Biol Chem 281:24171-24181, doi: 10.1074/jbc.M604507200
33. Górlach A, Diebold I, Schini-Kerth V, Berchner-Pfannschmidt U, Roth U, Brandes R, Kietzmann T, Busse R (2001) Circ Res 89:47-54, doi: 10.1161/hh1301.092678
34. Friday BB, Adjei AA (2008) Advances in targeting the Ras/Raf/MEK/Erk mitogen activated protein kinase cascade with MEK inhibitors for cancer therapy. Mol Pathol 14:342-346
35. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS (2005) Systemic Bevacizumab (Avastin) Therapy for Neovascular Age Related Macular Degeneration. Ophthalmol 112:1035-1047
36. Krishna M, Narang H (2008) The complexity of mitogen-activated protein kinases (MAPKs) made simple. Cell Mol Life Sci 65:3535-3544